Keros Therapeutics (KROS) stock: insider trades, news & valuation
Health Care · Net sellingShare price and insider trades
Keros Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $76K and 11 sold $181M of KROS stock on the open market.
Get emailed when insiders cluster-buy stocks like KROS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
KROS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $21K | 2 | $101K | 4 |
| Q2 2026 | $32K | 3 | $90K | 4 |
| Q1 2026 | $22K | 1 | $332K | 4 |
| Q4 2025 | — | 0 | $181M | 7 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Keros Therapeutics, Inc. insider reported open-market purchases totaling $76K, while 11 insiders reported sales totaling $181M. Among insiders with enough purchase history to measure, Jean Jacques Bienaime (Director) has the highest Insider Score at 66. 5 of 19 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
KROS stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 20SEC | Esther ChoGeneral Counsel | Sell | 4,48535,770 held (−11%) | $10.29 | $46K | +16.1% | — |
| Aug 20SEC | Lorena Raquel LernerChief Scientific Officer | Sell | 3,56827,559 held (−11%) | $10.29 | $37K | +16.1% | — |
| Aug 20SEC | Annita TaniniCorp. Controller & Vp, Finance | Sell | 1,22445,144 held (−3%) | $10.29 | $13K | +16.1% | — |
| Aug 20SEC | Charles W. NewtonDirector | Sell Plan | 55112,114 held (−4%) | $10.30 | $6K | +16.0% | — |
| Aug 19SEC | Jean Jacques BienaimeDirector | Buy | 1,00019,592 held (+5%) | $10.27 | $10K | +16.4% | 66 |
| Jul 17SEC | Jean Jacques BienaimeDirector | Buy | 1,00018,592 held (+6%) | $10.61 | $11K | +12.6% | 66 |
| Jun 17SEC | Jean Jacques BienaimeDirector | Buy | 1,00017,592 held (+6%) | $10.19 | $10K | +17.3% | 66 |
| Jun 15SEC | Charles W. NewtonDirector | Sell Plan | 55012,665 held (−4%) | $10.04 | $6K | +19.0% | — |
| Jun 8SEC | Julius KnowlesDirector | Sell Plan | 2,62510,958 held (−19%) | $10.73 | $28K | +11.4% | — |
| Jun 8SEC | Nima FarzanDirector | Sell Plan | 2,6259,767 held (−21%) | $10.73 | $28K | +11.4% | — |
| Jun 5SEC | Alpna SethDirector | Sell Plan | 2,6259,767 held (−21%) | $10.72 | $28K | +11.5% | — |
| May 19SEC | Jean Jacques BienaimeDirector | Buy | 1,0009,450 held (+12%) | $10.58 | $11K | +12.9% | 66 |
| Apr 17SEC | Jean Jacques BienaimeDirector | Buy | 1,0008,450 held (+13%) | $11.70 | $12K | +2.1% | 66 |
| Mar 11SEC | Jean Jacques BienaimeDirector | Buy | 2,0007,450 held (+37%) | $11.21 | $22K | +6.6% | 66 |
| Feb 20SEC | Jasbir SeehraCEO | Sell | 7,015385,708 held (−2%) | $16.17 | $113K | -26.1% | — |
| Feb 20SEC | Esther ChoGeneral Counsel | Sell | 4,74539,755 held (−11%) | $16.35 | $78K | -26.9% | — |
| Feb 20SEC | Keith RegnanteCFO | Sell | 4,73939,261 held (−11%) | $16.35 | $77K | -26.9% | — |
| Feb 20SEC | Lorena Raquel LernerChief Science Officer | Sell | 3,87331,127 held (−11%) | $16.35 | $63K | -26.9% | — |
| Oct 17SEC | (china) Iv L.p. Pontifax10% Owner | Sell | 2,284,612 | $17.75 | $40.6M | -32.7% | — |
| Oct 17SEC | (china) Iv L.p. Pontifax10% Owner | Sell | 1,226,412 | $17.75 | $21.8M | -32.7% | — |
| Oct 17SEC | (china) Iv L.p. Pontifax10% Owner | Sell | 1,121,045 | $17.75 | $19.9M | -32.7% | — |
| Oct 17SEC | (china) Iv L.p. Pontifax10% Owner | Sell | 155,262 | $17.75 | $2.8M | -32.7% | — |
| Oct 15SEC | Daniel Schneeberger10% Owner | Sell | 4,391,237 | $17.75 | $77.9M | -32.7% | 54 |
| Oct 15SEC | Daniel Schneeberger10% Owner | Sell | 743,358 | $17.75 | $13.2M | -32.7% | 54 |
| Oct 15SEC | Daniel Schneeberger10% Owner | Sell | 254,669 | $17.75 | $4.5M | -32.7% | 54 |
Insiders at Keros Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Daniel Schneeberger10% Owner | — | $95.7M | Oct 15, 2025 | 54 |
| (china) Iv L.p. Pontifax10% Owner | — | $85.0M | Oct 17, 2025 | — |
| Jean Jacques BienaimeDirector | $76K | — | Aug 19, 2026 | 66 |
| Esther ChoGeneral Counsel | — | $124K | Aug 20, 2026 | — |
| Jasbir SeehraCEO | — | $113K | Feb 20, 2026 | — |
| Lorena Raquel LernerChief Scientific Officer | — | $100K | Aug 20, 2026 | — |
| Keith RegnanteCFO | — | $77K | Feb 20, 2026 | — |
| Julius KnowlesDirector | — | $28K | Jun 8, 2026 | — |
| Nima FarzanDirector | — | $28K | Jun 8, 2026 | — |
| Alpna SethDirector | — | $28K | Jun 5, 2026 | — |
| Annita TaniniCorp. Controller & Vp, Finance | — | $13K | Aug 20, 2026 | — |
| Charles W. NewtonDirector | — | $11K | Aug 20, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
KROS stock: common questions
Are Keros Therapeutics, Inc. insiders buying KROS stock?
In the past 12 months, 1 insiders reported open-market purchases of KROS worth $76K. The latest was Director Jean Jacques Bienaime bought $10K of KROS at $10.27.
Are Keros Therapeutics, Inc. insiders selling KROS stock?
11 insiders reported sales worth $181M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is KROS's 52-week range?
Over the past year KROS has traded between $9.91 and $21.84. It last closed at $11.95 on Oct 9, 2026.